• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小儿神经内分泌肿瘤:具有惊人变异性的罕见恶性肿瘤。

Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability.

作者信息

Castle Jennifer T, Levy Brittany E, Chauhan Aman

机构信息

Department of Surgery, Markey Cancer Center, University of Kentucky, 800 Rose Street, Lexington, KY 40536, USA.

Department of Surgery, University of Kentucky, 800 Rose Street, Lexington, KY 40536, USA.

出版信息

Cancers (Basel). 2022 Oct 15;14(20):5049. doi: 10.3390/cancers14205049.

DOI:10.3390/cancers14205049
PMID:36291833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9599522/
Abstract

Neuroendocrine neoplasms (NENs) encompass a variety of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) which can arise anywhere in the body. While relatively rare in the pediatric population, the incidence of NENs has increased in the past few decades. These neoplasms can be devastating if not diagnosed and treated early, however, symptoms are variable and can be indolent for many years. There is a reported median of 10 years from the appearance of the first symptoms to time of diagnosis. Considering some of these neoplasms have a mortality rate as high as 90%, it is crucial healthcare providers are aware of NENs and remain vigilant. With better provider education and easily accessible resources for information about these neoplasms, awareness can be improved leading to earlier disease recognition and diagnosis. This manuscript aims to provide an overview of both the most common NENs as well as the rarer NENs with high lethality in the pediatric population. This review provides up to date evidence and recommendations, encompassing recent changes in classification and advances in treatment modalities, including recently completed and ongoing clinical trials.

摘要

神经内分泌肿瘤(NENs)包括多种神经内分泌瘤(NETs)和神经内分泌癌(NECs),它们可发生于身体的任何部位。虽然NENs在儿科人群中相对罕见,但在过去几十年中其发病率有所上升。如果不及早诊断和治疗,这些肿瘤可能具有毁灭性,然而,症状各不相同,且可能多年不明显。据报道,从首次出现症状到确诊的中位时间为10年。鉴于其中一些肿瘤的死亡率高达90%,医疗保健提供者了解NENs并保持警惕至关重要。通过更好的提供者教育以及获取有关这些肿瘤的信息的便捷资源,可以提高认识,从而实现疾病的早期识别和诊断。本手稿旨在概述儿科人群中最常见的NENs以及具有高致死率的罕见NENs。本综述提供了最新的证据和建议,涵盖了分类的最新变化和治疗方式的进展,包括最近完成和正在进行的临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5572/9599522/49b851cccc4f/cancers-14-05049-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5572/9599522/49b851cccc4f/cancers-14-05049-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5572/9599522/49b851cccc4f/cancers-14-05049-g001.jpg

相似文献

1
Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability.小儿神经内分泌肿瘤:具有惊人变异性的罕见恶性肿瘤。
Cancers (Basel). 2022 Oct 15;14(20):5049. doi: 10.3390/cancers14205049.
2
Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.基于国家数据库的日本肺及纵隔神经内分泌肿瘤的流行病学分析
Cancer Epidemiol. 2022 Apr;77:102116. doi: 10.1016/j.canep.2022.102116. Epub 2022 Feb 7.
3
World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.世界卫生组织胰腺神经内分泌肿瘤分级分类:来自中国大型医疗机构的综合分析。
BMC Cancer. 2020 Sep 22;20(1):906. doi: 10.1186/s12885-020-07356-5.
4
The classification of neuroendocrine neoplasms of the breast and its clinical relevance.乳腺神经内分泌肿瘤的分类及其临床意义。
Virchows Arch. 2022 Jul;481(1):3-12. doi: 10.1007/s00428-021-03223-1. Epub 2021 Oct 26.
5
Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021.1993年至2021年挪威神经内分泌肿瘤的发病率和患病率
J Neuroendocrinol. 2023 Apr;35(4):e13264. doi: 10.1111/jne.13264. Epub 2023 Mar 29.
6
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.《2022 年世卫组织神经内分泌肿瘤分类概述》。
Endocr Pathol. 2022 Mar;33(1):115-154. doi: 10.1007/s12022-022-09708-2. Epub 2022 Mar 16.
7
Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.比较不同原发器官的神经内分泌肿瘤、神经内分泌癌和非神经内分泌癌的转移模式。
J Korean Med Sci. 2023 Mar 20;38(11):e85. doi: 10.3346/jkms.2023.38.e85.
8
Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need.结直肠神经内分泌肿瘤:未满足的需求领域。
Neuroendocrinology. 2019;108(1):45-53. doi: 10.1159/000493767. Epub 2018 Sep 16.
9
Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.铂类/依托泊苷方案治疗晚期低分化肺神经内分泌癌的疗效:回顾性分析。
Front Endocrinol (Lausanne). 2023 Jan 30;14:1065599. doi: 10.3389/fendo.2023.1065599. eCollection 2023.
10
Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.神经内分泌肿瘤:二分法、起源与分类
Visc Med. 2017 Oct;33(5):324-330. doi: 10.1159/000481390. Epub 2017 Oct 16.

引用本文的文献

1
Safety and dosimetry of [Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study.[镥]镥-多柔比星-奥曲肽在生长抑素受体阳性的胃肠胰神经内分泌肿瘤、嗜铬细胞瘤和副神经节瘤青少年患者中的安全性和剂量测定:II期NETTER-P研究的初步分析
Eur J Nucl Med Mol Imaging. 2025 Apr 8. doi: 10.1007/s00259-025-07246-7.
2
Young-Onset Cancers-Early Steps in the Right Direction.青年发病型癌症——朝着正确方向迈出的早期步伐。
Cancers (Basel). 2023 May 4;15(9):2599. doi: 10.3390/cancers15092599.

本文引用的文献

1
Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis.围手术期类癌危象:一项系统评价与荟萃分析。
Cancers (Basel). 2022 Jun 16;14(12):2966. doi: 10.3390/cancers14122966.
2
Vasoactive intestinal peptide secreting tumour: An overview.血管活性肠肽分泌肿瘤:概述
World J Gastrointest Oncol. 2022 Apr 15;14(4):808-819. doi: 10.4251/wjgo.v14.i4.808.
3
A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N.
一项针对原发性难治性或复发性高危神经母细胞瘤患儿的镥-奥曲肽个性化高剂量给药方案的II期试验-LuDO-N。
Front Pediatr. 2022 Mar 10;10:836230. doi: 10.3389/fped.2022.836230. eCollection 2022.
4
Update on the clinical management of multiple endocrine neoplasia type 1.1 型多发性内分泌肿瘤的临床管理进展。
Clin Endocrinol (Oxf). 2022 Oct;97(4):409-423. doi: 10.1111/cen.14727. Epub 2022 Apr 1.
5
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.《2022 年世卫组织神经内分泌肿瘤分类概述》。
Endocr Pathol. 2022 Mar;33(1):115-154. doi: 10.1007/s12022-022-09708-2. Epub 2022 Mar 16.
6
Overview of the 2022 WHO Classification of Pituitary Tumors.《2022 年世卫组织垂体肿瘤分类概述》。
Endocr Pathol. 2022 Mar;33(1):6-26. doi: 10.1007/s12022-022-09703-7. Epub 2022 Mar 15.
7
hPG (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.人胃泌素原(循环中的前胃泌素),一种用于检测低分化神经内分泌癌和高分化神经内分泌肿瘤的新型血液生物标志物。
Cancers (Basel). 2022 Feb 9;14(4):863. doi: 10.3390/cancers14040863.
8
Role of Combined Ga DOTA-Peptides and F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms.镓标记的DOTA肽与氟代脱氧葡萄糖PET/CT联合应用在胃肠胰神经内分泌肿瘤评估中的作用
Diagnostics (Basel). 2022 Jan 22;12(2):280. doi: 10.3390/diagnostics12020280.
9
Peptide receptor radionuclide therapy induced carcinoid crisis: A case report.肽受体放射性核素治疗引发类癌危象:一例报告。
Med J Malaysia. 2022 Jan;77(1):128-131.
10
Recent Advances in the Diagnosis and Management of Carcinoid Syndrome.类癌综合征的诊断与治疗进展。
Dis Mon. 2022 Jul;68(7):101304. doi: 10.1016/j.disamonth.2021.101304. Epub 2021 Dec 28.